62466-11-9

Usage

Uses

Used in Pharmaceutical Industry:
Ethanone, 2-bromo-1-(3-methyl-2-thienyl)(9CI) is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to contribute to the development of new drugs with potential therapeutic applications. Its unique chemical structure allows for the creation of diverse medicinal compounds.
Used in Agrochemical Industry:
In the agrochemical sector, Ethanone, 2-bromo-1-(3-methyl-2-thienyl)(9CI) is employed as a precursor in the production of agrochemicals, such as pesticides and herbicides. Its reactivity enables the formation of active ingredients that can effectively control and manage pests and weeds in agricultural settings.
Used in Chemical Compound Manufacturing:
Ethanone, 2-bromo-1-(3-methyl-2-thienyl)(9CI) is utilized as a building block in the manufacturing of other chemical compounds, expanding its applications across various industries. Its versatility in chemical reactions allows for the creation of a wide range of products, from specialty chemicals to advanced materials.

Upstream product

• 13679-72-6 2-acetyl-3-methylthiophene 

Downstream Products

• 145084-78-2 1-[2-(3-Methyl-thiophen-2-yl)-2-oxo-ethyl]-5-phenyl-1H-benzo[e][1,4]diazepine-2,3-dione 3-oxime 
• 145084-76-0 3-Amino-1-[2-(3-methyl-thiophen-2-yl)-2-oxo-ethyl]-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 
• 145084-77-1 1,3-Dihydro-1-(3-methyl-2-thenoyl)methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 

Relevant academic research and scientific papers

Bicyclyl or heterobicyclylmethanesulfonylamino-substituted n-hydroxyformamides

Compounds of formula (I): R is hydrogen, alkyl, alkenyl, alkynyl, aryl, heteroaryl or heterocyclyl; and R1 is bicyclyl or heterobicyclyl, are useful in the treatment and prophylaxis of conditions mediated by s-CD23.

Substituted 4-amino-thiazol-2-yl compounds as cyclin-dependent kinase inhibitors

Pharmaceutical compositions containing effective amounts of CDK-inhibiting diaminothiazole compounds of the following formula (where R1and R2are as defined in the specification) or their salts, or prodrugs or active metabolites of such compounds or salts, are useful for treating disorders and diseases such as cancer: In preferred embodiments, R1and R2are independently unsubstituted or substituted carbocyclic or heterocyclic aryl ring structures. Compounds where R2is ortho-substituted aryl are especially potent inhibitors of CDKs such as CDK4.

4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases

This invention is directed to aminothiazole compounds of formula (I) wherein R1 is a substituted or unsubstituted group selected from : C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; C1-6-alkoxyl; C1-6-alcohol; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; carbonyl; ether; (C1-6-alkyl)-carbonyl; (C1-6-alkyl)-aryl; (C1-6-alkyl)-cycloalkyl; (C1-6-alkyl)-(C1-6-alkoxyl); aryl-(C1-6-alkoxyl); thioether; thiol; and sulfonyl; wherein when R1 is substituted, each substituent independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol, thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; and R2 is a carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, ring structure having a substituent at the position adjacent to the point of attachment, which ring structure is optionally further substituted, where each substituent of R2 independently is a halogen; haloalkyl; C1-6-alkyl; C1-6-alkenyl; C1-6-alkynyl; hydroxyl; C1-6-alkoxyl; amino; nitro; thiol; thioether; imine; cyano; amido; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen; carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, cycloalkyl; or carbocyclic or heterocyclic, monocyclic or fused or non-fused polycyclic, aryl; or a pharmaceutically acceptable salt of a compound of formula (I), or a prodrug or pharmaceutically active metabolite of a compound of formula (I) or pharmaceutically acceptable salt thereof, for inhibiting cyclin-dependent kinases (CDKs), such as CDK1, CDK2, CDK4, and CDK6. The invention is also directed to the therapeutic or prophylactic use of pharmaceutical compositions containing such compounds and to methods of treating malignancies and other disorders by administering effective amounts of such compounds.